Use of active surveillance for very low-risk prostate cancer rose from 11.6% of patients in 2010 to 27.3% in 2013, study finds.
Tinnitus is 3-fold more likely to develop in patients with versus without chronic kidney disease, new study shows.
PSA levels of 10 ng/mL or higher in men who have biochemically recurrent PCa after radical prostatectomy and a PSADT less than 12 months are at imminent risk for metastatic disease.
Targeting and treating systolic blood pressure to a lower range was associated with a 14% decreased risk of death, meta-analysis shows.
Cabozantinib reduced the risk of disease progression or death compared with sunitinib among patients with previously untreated advanced renal cell carcinoma.
Despite low infection rates, AVFs have a high risk of maturation failure and abandonment.
A European trial found a survival benefit from PCa screening and a US trial did not, but a new analysis finds that both trials provide compatible evidence that screening decreases PCa mortality.
Liraglutide-treated patients were 22% less likely than placebo recipients to experience a composite outcome of renal events.
No significant association found between marijuana use and change in estimated glomerular filtration rate or development of albuminuria.
Bosutinib treatment was associated with a 66% decrease in the annual rate of kidney enlargement.
Patients are more likely to receive intensity-modulated radiation therapy if they are managed by urology practices with an ownership interest in the modality, study finds.
Of 7 phosphate binders, iron-based agents were optimal when efficacy and safety are considered.
Researchers find no significant change in overall complication rate from 2010 to 2015, but hospital length of stay and need for transfusion have declined.
Prostate cancer patients accurately report their comorbidities, and participants in cancer clinical trials report more adverse events than trial investigators.
Men with 1 high-risk factor experience better outcomes following treatment than those with 2 or 3 high-risk factors, study finds.
Study of men with intermediate- or high-risk prostate cancer finds facility-level racial disparity in use of definitive treatment.
A detectable PSA nadir combined with shorter time to nadir after prostate cancer surgery is associated with a higher risk of biochemical recurrence.
Pilot study suggests intranasal theophylline may be worth further investigation as a treatment.
Except for gabapentin, evidence for 38 other treatments is weak and limited by small studies with a high risk of bias, new review finds.
Nearly 1 in 3 patients diagnosed with Gleason 3+4 favorable intermediate-risk prostate cancer had their disease upgraded or upstaged at radical prostatectomy.
The investigators assessed proteomic profiling of 80 proteins using a multiplex assay.
The odds of starting hemodialysis with an arteriovenous fistula are 31% lower for women compared with men.
A new study found a 52% higher risk for the future development of Parkinson's disease among men with erectile dysfunction.
Higher mortality was seen in association with an emergency department discharge with acute kidney injury vs no acute kidney injury.
Use of sevelamer was associated with a 14% decreased risk of death compared with non-use.
Researchers calculated that the absolute increase in lifetime risk of prostate cancer associated with vasectomy was just 0.6%.
Up to a 49% higher risk of death observed in patients who had a 400 ng/mL increase in serum ferritin from baseline values compared with patients who had relatively stable ferritin levels.
Japanese researchers conclude that a serum ferritin level below 90 ng/mL and TSAT of 20% or higher was optimal for achieving a hemoglobin level of 10 g/dL or higher.
Over a 10-year period, radical prostatectomy use increased steadily while radiotherapy use declined
Patients who underwent the minimally invasive procedure had a 36%, 50%, and 44% improvement in IPSS, quality of life, and peak flow rate, respectively, at 5 years.
Both findings on biopsy also predict a lower odds of high-grade cancer.
Symptomatic recurrence was associated with a nearly 2-fold higher risk of death from the time of recurrence versus surveillance-detected recurrence.
Prostate cancer patients on active surveillance who have no cancer found on confirmatory biopsy have a reduced risk of grade and volume reclassification.
CKD patients treated to a target systolic blood pressure of less than 120 mm Hg were 28% less likely to die early.
Anemic patients were 41% and 80% more likely to have coronary artery disease and peripheral artery disease than non-anemic patients.
Chronic kidney disease stage 3 is 23% more likely to develop in individuals in the highest versus lowest quintile of consumption of red and processed meat.
Radiotherapy for prostate cancer patients with persistently elevated PSA after radical surgery improved survival only among those with worse pathologic characteristics.
The risk for developing erectile dysfunction is 15% higher among men with than without gout.
All-cause hospitalizations in the US increased 410% from 1993 to 2014 among gout sufferers compared with 4.8% in the general population.
Patients often received sodium thiosulfate with other therapies.
Typically, about 2% to 20% of SHPT patients experience recurrence or persistence after conventional parathyroidectomy procedures, likely due to residual parathyroid tissue.
Most elderly CKD patients ultimately will not require or desire renal replacement therapy.
Some men who undergo multigene testing for inherited prostate cancer misinterpret findings of variants of uncertain significance.
A DASH-style diet is associated with a reduced risk of gout, whereas a Western diet is associated with a higher risk.
Opportunistic viral and fungal infections or malignancies develop in 34% of kidney transplant recipients, but these complications do not affect patient or graft survival.
High-KDPI kidneys can improve the likelihood of a functioning graft compared with waiting for a superior kidney.
Researchers report that matching deceased kidney donors and kidney recipients by cytomegalovirus serostatus optimizes high- and low-risk profiles.
Five-year graft survival rates among recipients of kidneys from living donors increased from 76.6% in 1985-1894 to 85.4% in 2009-2015.
Evidence to date provides no clear answer as to whether early or delayed RRT is the best approach.
Action taken to mitigate risks associated with ESA use and changes in payment policy did not result in a relative increase in death or major cardiovascular events.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)